A Study to Evaluate KIN-2787 in Subjects With BRAF Mutation Positive Solid Tumors
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and
preliminary efficacy of KIN-2787 in adults with BRAF-mutated advanced or metastatic solid
tumors.